Japanese
Title中枢性ベンゾジアゼピン受容体イメージング剤123I - イオマゼニルの第2相臨床試験 (第1報) - 投与量および適応疾患の検討 -
Subtitle技術報告
Authors鳥塚莞爾*1, 上村和夫*2, 融道男*3, 米倉義晴*4, 中川原譲二*5, 福山秀直*6, 松田一己*7, 森本清*8
Authors(kana)
Organization*1福井医科大学(現 ; 京都大学名誉教授), *2秋田県立脳血管研究センター, *3東京医科歯科大学神経精神科, *4京都大学脳病態生理学講座(現 ; 福井医科大学高エネルギー医学研究センター), *5中村記念病院脳神経外科, *6京都大学神経内科(現 ; 脳病態生理学講座), *7国立療養所静岡東病院(てんかんセンター)脳神経外科, *8香川医科大学精神神経科
Journal核医学
Volume33
Number2
Page179-190
Year/Month1996/2
Article報告
Publisher日本核医学会
Abstract「要旨」てんかん, 脳血管障害, 中枢神経変性疾患および精神神経障害等の各種脳疾患を対象に123I-イオマゼニルの有効性, 安全性および至適投与量を検討した. ベンゾジアゼピン受容体(BZR)結合能を反映すると考えられる投与後3時間のSPECT像(後期像)と, 脳血流像を比較すると, 脳梗塞症例では脳血流障害の程度と比較してBZR結合能の低下が軽度であることを示す所見が高頻度にみられた. 一方, 亜急性期脳梗塞では梗塞周辺の血流増加部位においてBZR結合能が相対的に低下している所見も散見された. その他の脳疾患群においては, 血流障害よりもBZR結合能の障害の方が著しい病態を示唆する所見が高頻度にみられた. 本剤の投与量として, 167MBqを中心とした111〜222MBqが適当であると考えられた. 本剤は安全性に問題はなく, また, 脳血流検査のみでは得難い, 各種脳疾患特有の脳病態生理に関してより詳細な情報が得られ, 脳疾患の病態診断に有用であることが示唆された.
Practice臨床医学：一般
Keywords123I-iomazenil, Benzodiazepine receptor, Central nervous system disorders, Phase 2 study, Neuronal damage.
English
TitlePhase 2 Clinical Study of 123I - Iomazenil in Various Cerebral Diseases : Part 1 - Examination of Injection Dose and Clinical Indications -
SubtitleTechnical Reports
AuthorsKanji TORiZUKA*1, Kazuo UEMURA*2, Michio TOHRU*3, Yoshiharu YONEKURA*4, Jyoji NAKAGAWARA*5, Hidenao FUKUYAMA*6, Kazumi MATSUDA*7, Kiyoshi MORIMOTO*8
Authors(kana)
Organization*1Fukui Medical School(currently Professor Emeritus, Kyoto University), *2Akita Research Institute for Brain and Blood Vessels, *3Department of Psychiatry, Tokyo Medical and Dental University, *4Department of Brain Pathophysiology, Kyoto University(currently Biomedical Imaging Research Center, Fukui Medical School), *5Department of Neurosurgery, Nakamura Memorial Hospital, *6Department of Neurology(currently Department of Brain Pathophysiology), Kyoto University, *7Department of Neurosurgery, National Epilepsy Center, Shizuoka-Higashi Hospital, *8Department of Neuropsychiatry, Kagawa Medical School
JournalThe Japanese Journal of nuclear medicine
Volume33
Number2
Page179-190
Year/Month1996/2
ArticleReport
PublisherTHE JAPANESE SOCIETY OF NUCLEAR MEDICINE
Abstract[Summary]A phase 2 study of 123I-Iomazenil(IMZ)was performed to evaluate its clinical usefulness in SPECT imaging of central-type benzodiazepine receptors(BZR). A total of 246 patients with various central nervous system disorders[82 with epilepsy, 94 with cerebrovascular disease(CVD), 47 with degenerative disorders, 14 with mental disorders relating to BZR and 9 with other diseases] were intravenously injected with 111-222MBq of IMZ. Early and late images were obtained 15 min and 180 min after injection as the mid-scan time, respectively. In comparison with regional cerebral blood flow(rCBF)images, the uptake of IMZ in the late images, which reflect the regional distribution of BZR, was relatively preserved compared to the uptake of CBF tracers in most of the patients with CVD. In the area of hyperperfusion in the subacute phase of cerebral infarction, however, the defects of IMZ uptake were accompanied by increased uptake of the CBF tracers. On the other hand, late IMZ uptake in most of the patients with the other diseases was decreased more significantly than the uptake of the CBF tracers, suggesting that cortical neuronal damage is more prominent than rCBF in these diseases compared to the vascular perfusional state. No adverse reactions were recognized relating to the IMZ administration. These results suggest that IMZ may provide us with valuable information for assessing pathophysiological state in the brain, which are difficult to achieve with other imaging modalities.
PracticeClinical medicine
Keywords123I-iomazenil, Benzodiazepine receptor, Central nervous system disorders, Phase 2 study, Neuronal damage.

【全文PDF】